Cytokinetics, Incorporated (NASDAQ: CYTK) announced that it is scheduled to report first quarter results on Tuesday, May 6, 2014 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company’s outlook for the future. Cytokinetics, Inc. (NASDAQ:CYTK) shares after opening at $12.05 moved to $13.26 on last trade day and at the end of the day closed at $1111. Company price to sales ratio in past twelve months was calculated as 15.32 and price to cash ratio as 6.03. Cytokinetics, Inc. (NASDAQ:CYTK) showed a positive weekly performance of 43.22%.
Array BioPharma Inc. (NASDAQ: ARRY) reports that Novartis has indicated that it will continue to honor its obligations under the Array-Novartis agreement relating to binimetinib (MEK162), including obligations relating to support for ongoing clinical trials as specified in the agreement. Array Biopharma Inc (NASDAQ:ARRY) shares advanced 7.63% in last trading session and ended the day on $4.09. ARRY return on equity ratio is recorded as 307.40% and its return on assets is -53.70%. Array Biopharma Inc (NASDAQ:ARRY) yearly performance is -34.14%.
Synthetic Biologics Inc (NYSEMKT: SYN) company recently announced the formation of a Clinical Advisory Board (CAB) to support development of the Company’s constipation-predominant irritable bowel syndrome (C-IBS) program. The Company also announced that pioneering gastroenterologist and lead investigator for the C-IBS program, Mark Pimentel, M.D., FRCP(C), of Cedars-Sinai Medical Center (CSMC), has joined Synthetic Biologics as Chairman of the newly formed CAB. Synthetic Biologics Inc (NYSEMKT:SYN) shares moved up 6.19% in last trading session and was closed at $3.09, while trading in range of $ 2.82 – 3.16 . Synthetic Biologics Inc (NYSEMKT: SYN) year to date (YTD) performance is 101.96
Prothena Corp (NASDAQ:PRTA)‘s stock had its “buy” rating reaffirmed by Citigroup Inc. in a research note issued on Thursday, ARN reports. They currently have a $60.00 price objective on the stock. Citigroup Inc.’s price objective points to a potential upside of 51.44% from the company’s current price. Prothena Corporation PLC (NASDAQ:PRTA) weekly performance is 41.15%. On last trading day company shares ended up $30.62.Prothena Corporation PLC (NASDAQ:PRTA) distance from 50-day simple moving average (SMA50) is 14.57%.
Leave a Reply